Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology.
Emergency department visits
Hospitalization
Intensification of oral therapy
Outpatients
Prognosis
Worsening heart failure
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
18
04
2023
received:
14
03
2023
accepted:
24
04
2023
medline:
12
7
2023
pubmed:
20
5
2023
entrez:
20
5
2023
Statut:
ppublish
Résumé
Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice.
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Adrenergic beta-Antagonists
0
Diuretics
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-791Subventions
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom
Informations de copyright
© 2023 European Society of Cardiology.
Références
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24:4-131.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-80.
Butler J, Braunwald E, Gheorghiade M. Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA. 2014;312:789-90.
Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3:252-9.
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol. 2023;81:413-24.
Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al.; PARADIGM-HF Investigators and Committees. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF). Circulation. 2016;133:2254-62.
Ambrosy AP, Parikh RV, Sung SH, Tan TC, Narayanan A, Masson R, et al. Analysis of worsening heart failure events in an integrated health care system. J Am Coll Cardiol. 2022;80:111-22.
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, de Boer RA, et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142:1623-32.
Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, Greene SJ, et al. In-hospital worsening heart failure. Eur J Heart Fail. 2015;17:1104-13.
Gualandro DM, Puelacher C, Chew MS, Andersson H, Lurati Buse G, Glarner N, et al.; BASEL-PMI Investigators. Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes. Eur J Heart Fail. 2023;25:347-57.
Kimmoun A, Takagi K, Gall E, Ishihara S, Hammoum P, El Beze N, et al. Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades. Eur J Heart Fail. 2021;23:420-31.
Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019;4:e406-20.
Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2021;6:952-6.
Butt JH, Fosbol EL, Gerds TA, Andersson C, McMurray JJV, Petrie MC, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. Eur J Heart Fail. 2020;22:1777-85.
Labrosciano C, Horton D, Air T, Tavella R, Beltrame JF, Zeitz CJ, et al. Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand. Eur J Heart Fail. 2021;23:31-40.
Hariharaputhiran S, Peng Y, Ngo L, Ali A, Hossain S, Visvanathan R, et al. Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand. Eur J Heart Fail. 2022;24:1519-28.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272-87.
Greene SJ, Triana TS, Ionescu-Ittu R, Shi S, Guerin A, DeSouza MM, et al. Patients hospitalized for de novo versus worsening chronic heart failure in the United States. J Am Coll Cardiol. 2021;77:1023-5.
Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al. The Heart Failure Association Atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail. 2021;23:906-14.
Storrow AB, Jenkins CA, Self WH, Alexander PT, Barrett TW, Han JH, et al. The burden of acute heart failure on U.S. emergency departments. JACC Heart Fail. 2014;2:269-77.
Blecker S, Ladapo JA, Doran KM, Goldfeld KS, Katz S. Emergency department visits for heart failure and subsequent hospitalization or observation unit admission. Am Heart J. 2014;168:901-8.e1.
Andersson C, Gerds T, Fosbol E, Phelps M, Andersen J, Lamberts M, et al. Incidence of new-onset and worsening heart failure before and after the COVID-19 epidemic lockdown in Denmark: a nationwide cohort study. Circ Heart Fail. 2020;13:e007274.
Cannata A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, et al. Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. Eur J Heart Fail. 2020;22:2219-24.
Cox ZL, Lai P, Lindenfeld J. Decreases in acute heart failure hospitalizations during COVID-19. Eur J Heart Fail. 2020;22:1045-6.
Frankfurter C, Buchan TA, Kobulnik J, Lee DS, Luk A, McDonald M, et al. Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronto, Canada. Can J Cardiol. 2020;36:1680-4.
Konig S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A, et al. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail. 2020;22:2190-201.
Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123-33.
Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al.; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-7.
Kaplon-Cieslicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022;24:335-50.
Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:935-44.
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16:560-5.
Shah A, Mentz RJ, Sun JL, Rao VN, Alhanti B, Blumer V, et al. Emergency department visits versus hospital readmissions among patients hospitalized for heart failure. J Card Fail. 2022;28:916-23.
Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, et al. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21:112-20.
Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, et al.; VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6:706-12.
Vaduganathan M, Cunningham JW, Claggett BL, Causland FM, Barkoudah E, Finn P, et al. Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC Heart Fail. 2021;9:374-82.
Madelaire C, Gustafsson F, Stevenson LW, Kristensen SL, Kober L, Andersen J, et al. One-year mortality after intensification of outpatient diuretic therapy. J Am Heart Assoc. 2020;9:e016010.
Khan MS, Greene SJ, Hellkamp AS, DeVore AD, Shen X, Albert NM, et al. Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the Change the Management of Patients with Heart Failure Registry. Circ Heart Fail. 2021;14:e008351.
Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
Van Aelst LNL, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20:738-47.
Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13:28-35.
Tomasoni D, Lombardi CM, Sbolli M, Cotter G, Metra M. Acute heart failure: more questions than answers. Prog Cardiovasc Dis. 2020;63:599-606.
Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al.; ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338-52.
Girerd N, Mewton N, Tartiere JM, Guijarro D, Jourdain P, Damy T, et al. Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail. 2022;24:750-61.
Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007;116:1549-54.
Fudim M, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. Eur Heart J. 2018;39:4255-6.
Fudim M, Ponikowski PP, Burkhoff D, Dunlap ME, Sobotka PA, Molinger J, et al. Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. Eur J Heart Fail. 2021;23:1076-84.
Tromp J, Beusekamp JC, Ouwerkerk W, van der Meer P, Cleland JGF, Angermann CE, et al. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. Eur J Heart Fail. 2022;24:645-52.
Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail. 2021;23:1750-8.
Metra M, Jankowska EA, Pagnesi M, Anker SD, Butler J, Dorigotti F, et al.; AFFIRM-AHF Investigators. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. Eur J Heart Fail. 2022;24:1928-39.
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al.; AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-904.
Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail. 2022;24:227-9.
Girerd N, Seronde MF, Coiro S, Chouihed T, Bilbault P, Braun F, et al.; INI-CRCT, Great Network, and the EF-HF Group. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail. 2018;6:273-85.
Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, Savarese G, Salsali A, et al. Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Heart Fail. 2022;10:651-61.
Savarese G, Lindenfeld J, Stolfo D, Adams K, Ahmad T, Desai NR, et al. Use of patient-reported outcomes in heart failure: from clinical trials to routine practice. Eur J Heart Fail. 2023;25:139-51.
Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2209-25.
Butler J, Spertus JA, Bamber L, Khan MS, Roessig L, Vlajnic V, et al.; VITALITY-HFpEF Study Group. Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial. Eur J Heart Fail. 2022;24:843-50.
Codina P, Lupón J, Borrellas A, Spitaleri G, Cediel G, Domingo M, et al. Head-to-head comparison of contemporary heart failure risk scores. Eur J Heart Fail. 2021;23:2035-44.
Alvarez-Garcia J, Ferrero-Gregori A, Puig T, Vazquez R, Delgado J, Pascual-Figal D, et al.; Investigators of the Spanish Heart Failure Network (REDINSCOR). A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE. Eur J Heart Fail. 2015;17:818-27.
Lee DS, Straus SE, Farkouh ME, Austin PC, Taljaard M, Chong A, et al.; COACH Trial Investigators. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32.
Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail. 2021;23:1610-32.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715-31.
Nunez J, de la Espriella R, Rossignol P, Voors AA, Mullens W, Metra M, et al. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Eur J Heart Fail. 2022;24:1751-66.
Israr MZ, Salzano A, Yazaki Y, Voors AA, Ouwerkerk W, Anker SD, et al.; BIOSTAT-CHF Consortium. Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail. 2020;22:1486-90.
Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318:713-20.
Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-ProBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?). Circulation. 2018;137:1671-83.
Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-52.
Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al.; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206.
Januzzi JL Jr, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012;33:2265-71.
Nunez J, Llacer P, Garcia-Blas S, Bonanad C, Ventura S, Nunez JM, et al. CA125-guided diuretic treatment versus usual care in patients with acute heart failure and renal dysfunction. Am J Med. 2020;133:370-80.e4.
Januzzi JL Jr, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Preserved Trial Study Group. Prognostic implications of N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved. JACC Heart Fail. 2022;10:512-24.
Januzzi JL Jr, Zannad F, Anker SD, Butler J, Filippatos G, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-Reduced trial. J Am Coll Cardiol. 2021;78:1321-32.
Davison BA, Senger S, Sama IE, Koch GG, Mebazaa A, Dickstein K, et al. Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. Eur J Heart Fail. 2021;23:43-57.
Nunez J, Bayes-Genis A, Revuelta-Lopez E, Ter Maaten JM, Minana G, Barallat J, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail. 2020;8:386-97.
Nunez J, de la Espriella R, Minana G, Santas E, Llacer P, Nunez E, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur J Heart Fail. 2021;23:1445-57.
Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, et al. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail. 2019;21:732-43.
Boorsma EM, Ter Maaten JM, Damman K, van Essen BJ, Zannad F, van Veldhuisen DJ, et al. Albuminuria as a marker of systemic congestion in patients with heart failure. Eur Heart J. 2023;44:368-80.
Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupon J, Latini R, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72:2309-20.
Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017;5:287-96.
Girerd N. Worsening renal function precedes and follows worsening heart failure. Eur J Heart Fail. 2022;24:1915-7.
Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:584-603.
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-19.
Chatur S, Vaduganathan M, Peikert A, Claggett BL, McCausland FR, Skali H, et al. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail. 2022;24:1906-14.
Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24:365-74.
Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail. 2012;5:54-62.
Pellicori P, Platz E, Dauw J, Ter Maaten JM, Martens P, Pivetta E, et al. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail. 2021;23:703-12.
Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37:1244-51.
Čelutkienė J, Lainscak M, Anderson L, Gayat E, Grapsa J, Harjola VP, et al. Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22:181-95.
Pellicori P, Shah P, Cuthbert J, Urbinati A, Zhang J, Kallvikbacka-Bennett A, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21:904-16.
Platz E, Merz AA, Jhund PS, Vazir A, Campbell R, McMurray JJ. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. Eur J Heart Fail. 2017;19:1154-63.
Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al.; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-66.
Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021;398:991-1001.
Zito A, Princi G, Romiti GF, Galli M, Basili S, Liuzzo G, et al. Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24:2333-41.
Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail. 2016;4:333-44.
Cleland JGF, Pellicori P. To master heart failure, first master congestion. Lancet. 2021;398:935-6.
Mullens W, Sharif F, Dupont M, Rothman AMK, Wijns W. Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study. Eur J Heart Fail. 2020;22:1912-9.
Latib A, Hashim Mustehsan M, Abraham WT, Jorde UP, Bartunek J. Transcatheter interventions for heart failure. EuroIntervention. 2023;18:1135-49.
van Veldhuisen DJ, Braunschweig F, Conraads V, Ford I, Cowie MR, Jondeau G, et al.; DOT-HF Investigators. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124:1719-26.
Galinier M, Roubille F, Berdague P, Brierre G, Cantie P, Dary P, et al.; OSICAT Investigators. Telemonitoring versus standard care in heart failure: a randomised multicentre trial. Eur J Heart Fail. 2020;22:985-94.
Koehler J, Stengel A, Hofmann T, Wegscheider K, Koehler K, Sehner S, et al. Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study. Eur J Heart Fail. 2021;23:186-94.
Zsilinszka R, Mentz RJ, DeVore AD, Eapen ZJ, Pang PS, Hernandez AF. Acute heart failure: alternatives to hospitalization. JACC Heart Fail. 2017;5:329-36.
Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042-51.
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137-55.
Mebazaa A, Solal AC, Colombo PC. Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel? Eur Heart J. 2023;44:51-3.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al.; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95.
Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44:41-50.
Trulls JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Snchez-Marteles M, Conde-Martel A, et al.; CLOROTIC Trial Investigators. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:411-21.
Collins SP, Pang PS, Fonarow GC, Yancy CW, Bonow RO, Gheorghiade M. Is hospital admission for heart failure really necessary? The role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol. 2013;61:121-6.
Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM, et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016;4:1-8.
Buckley LF, Stevenson LW, Cooper IM, Knowles DM, Matta L, Molway DW, et al. Ambulatory treatment of worsening heart failure with intravenous loop diuretics: a four-year experience. J Card Fail. 2020;26:798-9.
Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:65-70.
Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al.; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329:214-23.
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505-35.
Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2023;25:457-68.
Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, et al.; HeartMate II Clinical Investigators. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-7.
Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-7.
Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail. 2017;19:595-602.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
McMurray JJV, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, et al.; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21:665-75.
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Preserved Trial Study Group. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144:1284-94.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143:326-36.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98.
Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event. J Card Fail. 2023;29:922-30.
Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2022;80:1302-10.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-28.
Docherty KF, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020;41:2379-92.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al.; EMPEROR-Reduced Trial Committees and Investigators. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42:671-80.
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, et al.; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022;10:35-45.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-74.
Bedrouni W, Sharma A, Pitt B, Lam CSP, Ni J, Ferreira JP, et al. Timing of statistical benefit of mineralocorticoid receptor antagonists among patients with heart failure and post-myocardial infarction. Circ Heart Fail. 2022;15:e009295.
Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al.; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA. 2003;289:712-8.
Lam PH, Packer M, Fonarow GC, Faselis C, Allman RM, Morgan CJ, et al. Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial. Am J Med. 2020;133:e25-31.
Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, et al. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6:499-507.
Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, et al. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;78:2004-12.
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022;24:431-41.
Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42:3011-20.
Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, et al. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022;24:2029-36.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al.; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-93.
Butler J, Anstrom KJ, Armstrong PW. Comparing the benefit of novel therapies across clinical trials: insights from the VICTORIA trial. Circulation. 2020;142:717-9.
Tomasoni D, Adamo M, Bozkurt B, Heidenreich P, McDonagh T, Rosano GMC, et al. Aiming at harmony. Comparing and contrasting international HFrEF guidelines. Eur Heart J Suppl. 2022;24:L20-8.
Rao VN, Diez J, Gustafsson F, Mentz RJ, Senni M, Jankowska EA, et al. Practical patient care considerations with use of vericiguat after worsening heart failure events. J Card Fail. 2023;29:389-402.
Nelson MB, Gilbert ON, Duncan PW, Kitzman DW, Reeves GR, Whellan DJ, et al. Intervention adherence in REHAB-HF: predictors and relationship with physical function, quality of life, and clinical events. J Am Heart Assoc. 2022;11:e024246.
Pandey A, Kitzman DW, Nelson MB, Pastva AM, Duncan P, Whellan DJ, et al. Frailty and effects of a multidomain physical rehabilitation intervention among older patients hospitalized for acute heart failure: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2023;8:167-76.
Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al.; OPTIMIZE-HF Investigators and Coordinators. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;153: 82.e1-11.
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-48.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.